secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K/A
Filed at:   2026-09-03T20:39:01+00:00
Accession:  0001125345-26-000059
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics restates pro forma to treat CDMO sale as discontinued ops; net cash $110.8M
--------------------------------------------------------------------------------

- CDMO sale to Bora closed 6/30/26; gross proceeds $122.5M, net cash $110.8M after $8.8M costs; up to $5M contingent.
- Pro forma continuing ops net loss: Q1'26 $41.3M vs $36.8M hist; FY25 $91.2M vs $74.6M; FY24 $68.6M vs $67.0M; FY23 $11.3M vs $9.1M.
- CDMO revenue eliminated from continuing ops: Q1'26 $14.1M, FY25 $52.6M, FY24 $13.1M, FY23 $9.8M.
- Company now focuses on R&D pipeline; CDMO results reported as discontinued operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/0001125345-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/mgnx-20260903.htm
  HTML page:      https://secwatch.observer/filing/0001125345-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer